inhibitors has been conducted using flufenamic acid as a lead compound. Computational docking of the drug and itsanalogs in the MPO active site was first attempted. Several molecules were then synthesized and assessed using three procedures for the measurement of their inhibiting activity: (i) the taurine assay, (ii) the accumulation of compound II, and (iii) the LDL oxidation by ELISA. Most of the synthesized
Syntheses of flufenamic acid metabolites I and II and other N-aryl-anthranilic acids
作者:R. E. Bowman、K. D. Brunt、K. E. Godfrey、L. Kruszynska、A. A. Reynolds、R. I. Thrift、D. Waite、W. R. N. Williamson
DOI:10.1039/p19730000001
日期:——
The syntheses of two metabolites of flufenamicacid, 5-hydroxy-N-(ααα-trifluoro-m-tolyl)anthranilic acid and N-(4-hydroxy-ααα-trifluoro-m-tolyl)anthranilic acid, are described. Syntheses of a number of otherN-aryl-anthranilicacids, mono-, di-, tri-, and tetra-substituted in the aryl ring lacking a carboxy-group, and with substituents in both aryl rings, are reported.
The use of a cytochrome P-450 enzyme comprising SEQ ID NO: 110, or a variant enzyme having at least 70% identity thereto and having CYP-450 activity, for the hydroxylation of an organic compound, wherein the amino acid residue at position 291 is not threonine.